Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.59 |
| ▸ | MMP2 | P08253 | 5/20 | 0.59 |
| ▸ | MMP9 | P14780 | 5/20 | 0.59 |
| ▸ | EGFR | P00533 | 3/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8177236 | 1.00 | MMP1 (0.59) | MMP1MMP2MMP9EGFRHDAC1 | |
| SCHEMBL3620554 | 1.00 | MMP1 (0.59) | MMP1MMP2MMP9EGFRHDAC1 | |
| SCHEMBL3621504 | 0.86 | MMP1 (0.61) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL3621501 | 0.86 | MMP1 (0.61) | MMP1MMP2MMP9EGFRMAOB | |
| SCHEMBL3606597 | 0.83 | DHODH (0.76) | MMP1MMP2MMP9EGFRHDAC1 | |
| SCHEMBL3606596 | 0.83 | DHODH (0.76) | MMP1MMP2MMP9EGFRHDAC1 | |
| SCHEMBL3615601 | 0.77 | SMN1; SMN2 (0.60) | DHODHALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL3615604 | 0.77 | SMN1; SMN2 (0.60) | DHODHALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL3616078 | 0.77 | LMNA (0.50) | EGFRHDAC1MAOBDHODHALDH1A1 | |
| SCHEMBL3616077 | 0.77 | LMNA (0.50) | EGFRHDAC1MAOBDHODHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2099753-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-16 | — | — | EP | disclosed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074413-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | NOS3, PTGIS, NOS1 | MMP1 1120/4885MMP2 709/4885MMP9 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.